Literature DB >> 24035431

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.

Oliver Gautschi1, Solange Peters, Vincent Zoete, Franziska Aebersold-Keller, Klaus Strobel, Bernhard Schwizer, Astrid Hirschmann, Olivier Michielin, Joachim Diebold.   

Abstract

BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance. This information may help to develop effective targeted therapies for cancers with non-V600 BRAF mutations.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BRAF; Biomarker; Dabrafenib; Lung cancer; Melanoma; Targeted therapy; Vemurafenib

Mesh：

Substances：

Year:  2013        PMID： 24035431     DOI： 10.1016/j.lungcan.2013.08.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  11 in total

Review 1.  The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

Authors:  Alessia Spagnuolo; Matteo Muto; Fabio Monaco; Giuseppe Colantuoni; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 2.  Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.

Authors:  Suzanne A W Fuqua; Guowei Gu; Yassine Rechoum
Journal:  Breast Cancer Res Treat       Date:  2014-02-01       Impact factor: 4.872

3.  BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.

Authors:  Yuri Sheikine; Dean Pavlick; Samuel J Klempner; Sally E Trabucco; Jon H Chung; Mark Rosenzweig; Kai Wang; Vamsidhar Velcheti; Garrett M Frampton; Nir Peled; Molly Murray; Young Kwang Chae; Lee A Albacker; Laurie Gay; Hatim Husain; James H Suh; Sherri Z Millis; Venkataprasanth P Reddy; Julia A Elvin; Ryan J Hartmaier; Afshin Dowlati; Phil Stephens; Jeffrey S Ross; Trever G Bivona; Vincent A Miller; Shridar Ganesan; Alexa B Schrock; Sai-Hong Ignatius Ou; Siraj M Ali
Journal:  JCO Precis Oncol       Date:  2018-04-19

Review 4.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

5.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

Review 6.  Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.

Authors:  Sacha I Rothschild
Journal:  Cancers (Basel)       Date:  2015-05-26       Impact factor: 6.639

Review 7.  [Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

Authors:  Xiaoyan Kang; Nan Zhu; Xia Song
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-10-20

8.  Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

Authors:  Arpita Desai; Smitha P Menon; Grace K Dy
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

9.  Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.

Authors:  Laura J Tafe; Kirsten J Pierce; Jason D Peterson; Francine de Abreu; Vincent A Memoli; Candice C Black; Jason R Pettus; Jonathan D Marotti; Edward J Gutmann; Xiaoying Liu; Keisuke Shirai; Konstantin H Dragnev; Christopher I Amos; Gregory J Tsongalis
Journal:  Neoplasia       Date:  2016-09       Impact factor: 5.715

10.  Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

Authors:  Andrea Casadei Gardini; Elisa Chiadini; Luca Faloppi; Giorgia Marisi; Angelo Delmonte; Mario Scartozzi; Cristian Loretelli; Alessandro Lucchesi; Devil Oboldi; Alessandra Dubini; Giovanni Luca Frassineti; Paola Ulivi
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.